Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025
Arcellx shares closed at $72.08 on December 9, down 2.7% after surging 13.6% pre-market on positive Phase 2 data for its multiple myeloma therapy anito-cel at ASH 2025. The iMMagine-1 study showed a 96% overall response rate and no delayed neurotoxicities in 117 heavily pretreated patients. Analysts maintain a “Strong Buy” consensus and anticipate a 2026 commercial launch.